SCHEMBL48530

SCHEMBL48530

Cc1nc(NC(=O)NCc2ccccn2)sc1-c1ccc(S(C)(=O)=O)c(F)c1

nearest known ligand 0.65

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 10/20 0.65
PIK3CA P42336 10/20 0.65
PIK3CG P48736 10/20 0.65
PIK3CB P42338 9/20 0.65
CLK1 P49759 1/20 0.59
CLK2 P49760 1/20 0.59
PI4KB Q9UBF8 1/20 0.59
KMT2A Q03164 2/20 0.46
NPC1 O15118 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
ROCK2 O75116 1/20 0.44
ROCK1 Q13464 1/20 0.44
ALOX15 P16050 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL48594 0.92 PIK3CD (0.66) PIK3CDPIK3CAPIK3CGPIK3CBCLK1
SCHEMBL1786401 0.89 PIK3CD (0.67) PIK3CDPIK3CAPIK3CGPIK3CBCLK1
SCHEMBL48735 0.88 PIK3CD (0.55) PIK3CDPIK3CAPIK3CGPIK3CBPI4KB
SCHEMBL1785318 0.85 PIK3CD (0.67) PIK3CDPIK3CAPIK3CGPIK3CBCLK1
SCHEMBL48455 0.85 PIK3CD (0.75) PIK3CDPIK3CAPIK3CGPIK3CBCLK1
SCHEMBL1788182 0.84 PIK3CD (0.77) PIK3CDPIK3CAPIK3CGPIK3CBCLK1
SCHEMBL1786751 0.83 PIK3CG (0.65) PIK3CDPIK3CAPIK3CGPIK3CBCLK1
SCHEMBL48832 0.83 PIK3CD (0.75) PIK3CDPIK3CAPIK3CGPIK3CBCLK1
SCHEMBL1785640 0.82 PIK3CD (0.63) PIK3CDPIK3CAPIK3CGPIK3CBCLK1
SCHEMBL12363422 0.82 PIK3CD (0.80) PIK3CDPIK3CAPIK3CGPIK3CBCLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1480962-B1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS NOVARTIS AG (CH) 2011-08-24 EP claimed
US-8129541-B2 5-phenylthiazole derivatives and use as PI3 kinase inhibitors NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-1480962-B1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS NOVARTIS AG (CH) 2011-08-24 EP disclosed
US-20100093690-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS BRUCE IAN 2010-04-15 US disclosed
US-7687637-B2 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors NOVARTIS AG (CH) 2010-03-30 US disclosed
CN-100548996-C 5-phenylthiazole derivatives and their use for the preparation of medicaments NOVARTIS AG (CH) 2009-10-14 CN disclosed
CN-1639139-A 5-phenylthiazole derivatives and use as PI3 kinase inhibitors NOVARTIS AG (CH) 2005-07-13 CN disclosed
US-20050119320-A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors NOVARTIS AG (CH) 2005-06-02 US disclosed
EP-1480962-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS Novartis AG (CH) 2004-12-01 EP disclosed
WO-2003072557-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS NOVARTIS AG (CH) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093690-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS PIK3CA, PIK3R5, PIP5K1B PIK3CD 4/4885PIK3CA 1/4885PIK3CG 8/4885
US-20050119320-A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors PIK3CA, PIK3R5, PIP5K1B PIK3CD 4/4885PIK3CA 1/4885PIK3CG 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.